Clinical trial
Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or…
NCT00112476 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00112476 |
|---|---|
| Title | Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid Tumors |
| Official title | A Phase I Study of Intravenous CCI-779 in Combination With Bryostatin-1 in Solid Tumors (10038414) |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Recurrent Melanoma, Recurrent Renal Cell Cancer, Stage IV Melanoma, Stage IV Renal Cell Cancer, Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | bryostatin 1, temsirolimus |
| Enrollment | 24 |
| Start date | Mar 1, 2005 |
| Primary completion | Jul 1, 2010 |
| First posted | Jun 3, 2005 |
| Last update posted | May 3, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: